Table 2.
Success of HCV genotyping using the established method.
| LiPA genotypea | 1 | 2 | 3 | 4 | 5 | 6 | 1a/4 | 2b/1a | Unknownb | NCc | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Samples amplified | 78 | 37 | 100 | 13 | 4 | 1 | 2 | 1 | 1 | 1 | 238 |
| Product in gel | 71 | 32 | 96 | 12 | 4 | 1 | 2 | 1 | 0 | 0 | 219 |
| No product in gel | 7 | 5 | 4 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 19 |
| Samples sequenced | 64 | 30 | 92 | 7 | 4 | 1 | 1 | 1 | 1 | 0 | 201 |
| Retrieved genotype results | 64 | 28 | 91 | 7 | 4 | 1 | 1 | 1 | 0 | 0 | 197 |
a
Versant HCV Genotype 2.0 (Siemens Healthcare, Tarrytown, NY, USA) line probe assay.
b
Genotype could not be identified using the LiPA method.
c
Negative control, a patient sample tested negative for HCV.